Drug Sales Trends for ZOFRAN

Payment Methods and Pharmacy Types for ZOFRAN (2004)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
INSIDE ANOTHER STORE	$534,753
INSIDE HMO/CLINIC/HOSPITAL	$1,015,140

Units Sold by Pharmacy Type

Pharmacy Type	Units
INSIDE ANOTHER STORE	15,675
INSIDE HMO/CLINIC/HOSPITAL	17,115

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$5,331,836
PRIVATE INSURANCE	$278,974,070

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for ZOFRAN

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
ZOFRAN			2022
ZOFRAN			2021
ZOFRAN			2020
ZOFRAN			2019
ZOFRAN			2018
ZOFRAN			2017

Zofran Market Analysis and Sales Projections: Ondansetron Generics, Demand, Pricing, and Patent Status

Last updated: September 8, 2026

Zofran is the original branded formulation of ondansetron, a 5-HT3 receptor antagonist used to prevent nausea and vomiting associated with chemotherapy, radiotherapy, surgery, and other clinical settings. The product has lost U.S. market exclusivity. Commercial value is now concentrated in generic ondansetron tablets, orally disintegrating tablets, oral solution, and injection rather than the Zofran brand.

The market outlook is stable in volume and declining in price. A reasonable base case is low-single-digit annual unit growth with flat-to-declining market revenue through 2030, subject to hospital purchasing, injectable supply conditions, and demand in oncology and perioperative care.

What is Zofran and how is ondansetron used?

Zofran contains ondansetron hydrochloride, an antiemetic that blocks serotonin 5-HT3 receptors. FDA-approved uses include:

• Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy
• Prevention of nausea and vomiting associated with radiotherapy
• Prevention of postoperative nausea and vomiting
• Pediatric use in selected indications and dosage forms

Ondansetron is available in several dosage forms:

Dosage form	Primary market	Commercial status
Immediate-release tablets	Retail and institutional	Generic
Orally disintegrating tablets	Retail, outpatient, emergency care	Generic
Oral solution	Pediatric and selected outpatient use	Generic
Injection	Hospitals, surgery centers, oncology	Generic
Branded Zofran tablets and ODT	Historical branded market	Largely displaced by generics

The product is often prescribed off-label for nausea and vomiting related to gastroenteritis, pregnancy, migraine, and other conditions. Those uses contribute to demand but are not equivalent to FDA-approved indications.

What is the current market status of Zofran?

The current market is a mature generic market, not a conventional branded pharmaceutical market. GlaxoSmithKline originally commercialized Zofran, but patent expiry enabled multiple generic manufacturers to enter the U.S. market. FDA-approved generic products are listed in the Orange Book under ondansetron dosage forms and strengths [1].

Brand-level Zofran sales are no longer a reliable measure of ondansetron demand. The relevant commercial metrics are:

1. Total prescriptions and hospital units
2. Generic net price per unit
3. Injectable contract volume
4. Dosage-form mix
5. Manufacturer supply reliability
6. Formulary position and wholesaler share

Retail demand is relatively price-sensitive because multiple generic suppliers compete. Hospital injectable demand is more exposed to shortages, purchasing contracts, and manufacturing interruptions.

When did Zofran lose exclusivity?

Zofran’s primary U.S. composition-of-matter patent expired in the mid-2000s. FDA approval of ondansetron occurred in 1991, and generic competition followed after expiration of the principal patent and related regulatory exclusivities [1][2].

Milestone	Approximate timing	Commercial effect
Original U.S. approval	1991	Launch of branded ondansetron
Core patent protection	Through the mid-2000s	Protected branded pricing
Generic entry	Mid-2000s	Rapid price erosion
Mature generic market	2010s onward	High supplier competition
Current position	2020s	Low brand relevance; generic-driven volume

Exact patent protection depended on dosage form, patent listing, pediatric exclusivity, and market segment. The commercial loss of exclusivity occurred more than a decade ago, eliminating the basis for a conventional branded Zofran forecast.

What patents protect Zofran and ondansetron?

The principal patent estate protected the ondansetron active ingredient and related pharmaceutical compositions. Historical U.S. patent protection included patents associated with ondansetron and its use as an antiemetic. The main commercial patent barrier has expired.

Current patent risk is limited compared with products that have active formulation or device estates. Potentially relevant protections can still arise from:

• New combinations
• Novel dosing regimens
• Abuse-deterrent or modified-release systems
• Drug-device configurations
• Manufacturing processes
• New therapeutic indications

These rights would not restore broad exclusivity for standard ondansetron tablets or injection unless they covered a commercially important product and were enforceable against the relevant generic product.

What is the Orange Book status of Zofran?

FDA’s Orange Book lists approved ondansetron products and associated patents or exclusivity information where applicable [1]. The historical Zofran listings include multiple dosage forms and strengths.

The Orange Book is important for determining:

• Whether a listed patent remains active
• Whether an ANDA applicant may file a Paragraph IV certification
• Whether a generic product has an approved dosage form
• Whether a listed patent applies to tablets, ODT, oral solution, or injection
• Whether pediatric or other regulatory exclusivity remains

Because the central Zofran exclusivity period has expired, current generic competition is governed primarily by ANDA approvals, manufacturing economics, procurement contracts, and supply availability.

Which companies compete in the ondansetron market?

The market has included large generic manufacturers and specialty suppliers such as:

• Teva Pharmaceutical Industries
• Sandoz
• Hikma Pharmaceuticals
• Fresenius Kabi
• Pfizer, including hospital injectable operations
• Amneal Pharmaceuticals
• Rising Pharmaceuticals
• Dr. Reddy’s Laboratories
• Cipla
• Aurobindo Pharma
• Viatris and related legacy Mylan operations

Supplier participation varies by dosage form and jurisdiction. Injectable ondansetron is more concentrated than oral tablets because sterile manufacturing requires higher capital investment, regulatory compliance, and supply-chain controls.

How large is the Zofran and ondansetron market?

Public companies generally do not report ondansetron revenue as a separate line item. The molecule is sold across multiple generic labels, channels, and countries. As a result, a precise global market size cannot be derived from branded-company financial statements alone.

The market has three economically distinct segments:

Segment	Demand profile	Pricing profile	Outlook
Retail oral tablets	Broad outpatient use	Highly competitive	Stable volume, declining price
ODT products	Convenience and pediatric use	Moderate generic competition	Stable to modest growth
Hospital injection	Surgery, oncology, emergency care	Contract-driven	Stable demand, supply-sensitive

On a volume basis, ondansetron remains commercially durable because it is inexpensive, familiar to clinicians, available in several formulations, and used in high-frequency care settings. On a revenue basis, the market is materially smaller than during the branded Zofran period.

What are the sales projections for Zofran and generic ondansetron?

The following forecast applies to the U.S. ondansetron market rather than the discontinued or largely inactive branded Zofran business. It uses an indexed 2024 market revenue base of 100 because manufacturers do not disclose a consolidated ondansetron revenue figure.

Year	Base-case market index	Unit-volume growth	Price trend	Market interpretation
2024	100	Base year	Base year	Mature generic market
2025	99	1% to 2%	-2% to -4%	Continued generic price pressure
2026	98	1% to 2%	-2% to -4%	Stable demand, lower net price
2027	97	0% to 2%	-2% to -3%	Mature market conditions
2028	96	0% to 2%	-1% to -3%	Limited revenue expansion
2029	95	0% to 2%	-1% to -3%	Injectable supply may affect pricing
2030	94	0% to 2%	-1% to -3%	Long-term revenue erosion

Scenario analysis

Scenario	2030 revenue index	Assumptions
Downside	80-88	Aggressive price competition, additional suppliers, stable clinical demand
Base case	90-98	Low unit growth and continued annual price erosion
Upside	105-115	Injectable shortages, higher hospital pricing, expanded global demand, or new formulation adoption

The branded Zofran business is expected to remain commercially immaterial relative to generic ondansetron. Any residual brand revenue would likely come from limited institutional contracts, legacy prescribing, or non-U.S. markets.

What factors will drive ondansetron sales through 2030?

Oncology and radiotherapy demand

Chemotherapy and radiotherapy remain core demand drivers. Growth in cancer incidence can support antiemetic volume, although newer antiemetic regimens may reduce reliance on ondansetron as a sole agent.

Surgical procedures

Postoperative nausea and vomiting prevention supports hospital and ambulatory surgery demand. Growth in outpatient procedures can increase use of injectable and orally administered antiemetics.

Pediatric and outpatient use

The ODT and oral-solution formats remain relevant in pediatric care and settings where swallowing tablets is difficult. Formulation convenience can support price premiums, but generic competition limits the magnitude of those premiums.

Hospital shortages

Shortages of injectable antiemetics can produce temporary price increases and supplier substitutions. These effects are usually episodic and do not create durable branded exclusivity.

Generic procurement

Large wholesalers, group purchasing organizations, hospitals, and retail pharmacies generally prioritize price, supply continuity, regulatory compliance, and product availability. Brand loyalty is weak.

What generic entry risks exist for Zofran?

Generic entry risk is no longer a future event. It has already occurred and reshaped the market. The relevant risks now concern additional competition and substitution:

• New ANDA approvals can reduce prices
• Hospital contracts can shift volume rapidly
• Retail pharmacies can substitute among approved suppliers
• Injectable products face manufacturing and inspection risk
• One supplier’s shortage can temporarily benefit competitors
• ODT products may retain modest pricing differentiation
• International markets may have different patent and regulatory timelines

A new generic entrant would face low clinical-development risk but meaningful manufacturing, distribution, and procurement barriers.

How strong is the remaining Zofran patent estate?

The remaining estate is weak for standard ondansetron products because the principal patent protection expired years ago. Patent strength is better characterized by product segment:

Product area	Current patent strength	Commercial barrier
Standard tablet	Low	Generic competition
Standard ODT	Low to moderate	Formulation and regulatory execution
Oral solution	Low	Manufacturing and distribution
Injection	Low to moderate	Sterile manufacturing and supply reliability
New combination product	Potentially moderate	Depends on claim scope and validity
New method of use	Potentially moderate	Enforcement and prescribing behavior

A patent covering a narrow method of use would have limited commercial value unless it materially changed prescribing or was tied to an FDA-approved labeling indication.

What litigation or Paragraph IV activity affects Zofran?

The major legal event was the historical generic challenge and subsequent market entry after expiry of core patent protection. There is no current, widely recognized patent dispute that restores exclusivity for standard Zofran products in the U.S.

Paragraph IV risk is therefore most relevant to future reformulations or new ondansetron products, not the established generic market. A new Paragraph IV case would need to target an active listed patent, and the commercial value would depend on whether the patent covers a meaningful share of prescriptions.

What is the regulatory status of ondansetron?

Ondansetron is FDA-approved and available through both NDA and ANDA pathways. Generic products must demonstrate pharmaceutical equivalence and bioequivalence to the applicable reference product. FDA approval does not prevent substitution among therapeutically equivalent products where state pharmacy rules and payer policies permit it [1][3].

The product is not a biologic, so biosimilar regulation is not applicable. Competitive entry occurs through the generic-drug pathway rather than the biosimilar pathway.

How does Zofran compare with competing antiemetics?

Product	Class	Main competitive position
Ondansetron	5-HT3 antagonist	Low cost, broad familiarity
Granisetron	5-HT3 antagonist	Alternative dosing and formulation options
Palonosetron	Long-acting 5-HT3 antagonist	Longer duration; stronger specialty positioning
Aprepitant and fosaprepitant	NK1 antagonists	Used in combination for higher-risk chemotherapy
Olanzapine	Antipsychotic used as antiemetic	Increasing role in selected oncology regimens
Metoclopramide	Dopamine antagonist/prokinetic	Lower-cost alternative in selected settings
Promethazine	Antihistamine/phenothiazine	Broad antiemetic use with different safety profile

Ondansetron remains competitive where low acquisition cost, predictable tolerability, and flexible dosage forms matter. It is less differentiated in high-risk chemotherapy, where multi-drug antiemetic regimens and longer-acting agents are used.

What is the investment outlook for Zofran?

Zofran is not an attractive branded-product growth asset. The investment case is a mature generic supply opportunity, particularly in:

• Injectable manufacturing
• Hospital contract supply
• Reliable sterile production
• Multi-product generic portfolios
• Geographic markets with limited competition
• ODT and pediatric dosage-form capabilities

Revenue growth is constrained by price erosion. Margin performance depends more on manufacturing efficiency, capacity utilization, shortage conditions, and contract discipline than on patent protection.

Key Takeaways

• Zofran is the historical brand for ondansetron, a mature generic antiemetic.
• U.S. exclusivity ended in the mid-2000s.
• The commercial market now consists mainly of generic tablets, ODT, oral solution, and injection.
• Brand Zofran revenue is expected to remain immaterial relative to total ondansetron volume.
• Base-case market revenue is likely to decline at a low-single-digit annual rate through 2030.
• Injectable ondansetron has stronger supply and manufacturing barriers than oral products.
• Patent strength is low for standard products and potentially higher only for narrow new formulations or uses.
• No biosimilar pathway applies because ondansetron is a small-molecule drug.
• The primary commercial risks are price erosion, procurement pressure, and manufacturing interruptions.

FAQs

Is Zofran still sold as a brand-name drug?

Brand-name Zofran has been largely displaced by generic ondansetron in the U.S. Availability and marketing status can differ by dosage form and country.

Is ondansetron more profitable as a tablet or injection?

Injectable ondansetron can offer stronger supply-based economics because sterile manufacturing limits the number of qualified suppliers. Tablets face more intense generic price competition.

Does Zofran have remaining patent protection?

The core patent protection that supported branded Zofran sales expired years ago. Any remaining rights would generally relate to narrow formulations, methods, or jurisdictions rather than standard ondansetron products.

Can a new company launch a generic Zofran product?

A company can seek FDA approval through the ANDA pathway if it satisfies applicable pharmaceutical-equivalence, bioequivalence, manufacturing, labeling, and regulatory requirements. Commercial success would depend on pricing and supply reliability.

Will ondansetron sales grow with cancer incidence?

Cancer incidence can increase demand for antiemetics, but ondansetron volume growth may be moderated by combination regimens, newer long-acting agents, treatment changes, and generic price erosion.

References

1. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. Food and Drug Administration. (2014). Approved drug products with therapeutic equivalence evaluations. FDA.
4. GlaxoSmithKline plc. (Various years). Annual reports and financial statements.
5. National Cancer Institute. (n.d.). Nausea and vomiting related to cancer treatment. https://www.cancer.gov/